#China #Guangzhou #NASDAQ #digital healthcare #POMDOCTOR

Pomdoctor Limited Faces Nasdaq Compliance Challenges

POMDOCTOR LIMITED, a notable player in the digital healthcare sector, has recently come under scrutiny from The Nasdaq Stock Market, having received notifications regarding its compliance with listing requirements. The notifications were sent on October 28, 2026, signaling critical issues for the company as it strives to maintain its listing status on this prestigious exchange.

Known for its innovative approaches in AI-enabled healthcare solutions, Pomdoctor now faces two considerable challenges as posed by Nasdaq's Listing Qualifications Department. The first notification reveals a significant drop in the company's market value of listed securities (MVLS), which fell below the required $50 million threshold. Between September 16 and October 27, 2026, Pomdoctor's MVLS has not met Nasdaq Listing Rule 5450(b)(2)(A). As stipulated by Nasdaq Listing Rule 5810(c)(3)(C), the company has a compliance period of 180 calendar days—until April 26, 2027—to rectify this situation. If during this compliance period, the company manages to restore its MVLS above the specified threshold for at least ten consecutive business days, confirmation of compliance will be granted, and the issue resolved.

The second letter indicates that Pomdoctor also failed to meet the minimum market value of publicly held shares (MVPHS), which is set at $15 million under Nasdaq Listing Rule 5450(b)(23)(C). Like the MVLS requirement, the company is allowed a 180-day compliance period to address this deficiency, with the same criteria for closure on verification once compliance is achieved.

The ramifications of failing to address these compliance issues before the deadlines are severe. If Pomdoctor doesn't regain compliance, it could face delisting, which would severely impact its market presence and investor confidence. The company has stated its commitment to monitoring both MVLS and MVPHS closely, evaluating options to regain compliance effectively and promptly.

As Pomdoctor navigates this turbulent phase, the broader implications of compliance in the stock market become increasingly pronounced, especially for emerging digital healthcare firms that are operating at the intersection of technology and healthcare. Investors are encouraged to remain vigilant, considering the risks tied to stock market fluctuations, particularly as the landscape becomes more competitive and regulatory scrutiny intensifies.

In the context of innovation in healthcare, Pomdoctor continues to aim for advancement in AI-driven solutions and predictive healthcare capabilities, leveraging resources from physicians, wearable tech, and real-world healthcare data. The company believes this strategic pivot will not only uphold its standing but also drive significant growth and shareholder value in the future. However, it remains to be seen whether these ambitious plans will suffice amidst potential delisting threats and market pressures.

In conclusion, Pomdoctor's future on the Nasdaq could be determined in the coming months as it seeks to regain compliance with essential listing requirements that could dictate its operational viability and growth trajectory.

About POMDOCTOR LIMITED

Pomdoctor is dedicated to enhancing healthcare through cutting-edge digital solutions, focusing on personalized, data-driven healthcare. While poised for growth, the current compliance challenges pose significant hurdles that the company must overcome to ensure sustained operational success.

This press release includes forward-looking statements that involve uncertainties. The company acknowledges these risks and commits to keeping stakeholders informed as it negotiates these developments, aiming to bolster its compliance and secure its place within the Nasdaq framework.